Different levels in blood cell samples of EMT-markers for the diagnosis of cancer, in particular of colorectal (CRC) and pancreatic (PC) cancer

• Main Authors: CELESTI GIUSEPPE, LAGHI LUIGI
• Format: Patent
• Language: Chinese; English
• Published: 24.08.2016
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The present invention concerns a method for determining if a subject is affected by a colorectal or pancreatic cancer or for determining the stage and/or the progression of a colorectal cancer. The presence of a panel of mRNAs encoding for transcription factors/genes involved in epithelial to mesenchymal transition in a blood sample is measured, wherein different mRNA levels of a set of genes comprising TWIST1, SLUG, ZEB2, ZEB1and CDH1, are indicative of colorectal cancer or pancreatic cancer diagnosis, and/or of colorectal cancer stage at diagnosis, and/or of CRC metastatic progression after surgery. The invention concerns also the use of kits to work the method. 本发明涉及种确定对象是否患结直肠癌和胰腺癌或确定结直肠癌的阶段和/或进展的方法。测定血液样品中多个编码参与上皮细胞间质转型的转录因子/基因的mRNA存在与否，其中包括TWIST1、SLUG、ZEB2、ZEB1和CDH1的多个基因具有不同的mRNA水平，由此指示结直肠癌或胰腺癌诊断，和/或结直肠癌的诊断分期，和/或CRC的术后转移性进展。本发明还涉及使用试剂盒来实现该方法。